Q3 2024 marks a potential pivot in the evolution of cell, gene, and RNA therapies. While we saw only one new approval (Tecelra for synovial sarcoma), there are dynamic shifts deeper in the pipeline. The field is steadily diversifying; 51% of newly initiated gene therapy trials are now for non-oncology indications, up from just 39% year-over-year. The maturation of clinical research in these therapeutic areas evidences a progression of the field, which we expect to accelerate.

Dealmaking held steady at 101 transactions, but we’re reporting a substantial rebound in start-up financing. The tripling of seed and Series A rounds to $484 million signals a resurgence of confidence in next-generation CGT technologies. Coupled with strategic CDMO acquisitions, we’re watching this field mature in real-time, and it’s primed for breakthrough innovations.

For the full report, please download the PDF version at the top of this page in collaboration with ASGCT.